Publications by authors named "Julie Lotharius"

Claim this Profile
S
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.
James S McCarthy, Julie Lotharius, Thomas Rückle, Stephan Chalon, Margaret A Phillips

Lancet Infect Dis· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.
Margaret A Phillips, Julie Lotharius, Kennan Marsh, John White, Anthony Dayan

Sci Transl Med· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models.
Sarah Schleiferböck, Christian Scheurer, Masataka Ihara, Isamu Itoh, Ian Bathurst, Julie Lotharius

Drug Des Devel Ther· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repositioning: the fast track to new anti-malarial medicines?
Julie Lotharius, Francisco Javier Gamo-Benito, Iñigo Angulo-Barturen, Julie Clark, Michele Connelly

Malar J· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo activity of solithromycin (CEM-101) against Plasmodium species.
Sergio Wittlin, Eric Ekland, J Carl Craft, Julie Lotharius, Ian Bathurst

Antimicrob Agents Chemother· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in antimalarial drug discovery.
Jeremy N Burrows, Didier Leroy, Julie Lotharius, David Waterson

Future Med Chem· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of single enantiomer (+)-mefloquine compared with racemic mefloquine in healthy persons.
Robert Tansley, Julie Lotharius, Anthony Priestley, Fiona Bull, Stephan Duparc

Am J Trop Med Hyg· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIF prolyl hydroxylase inhibition increases cell viability and potentiates dopamine release in dopaminergic cells.
Jens Leander Johansen, Thomas Nikolaj Sager, Julie Lotharius, Louise Witten, Arne Mørk

J Neurochem· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells.
Stefan Schildknecht, Dominik Pöltl, Daniel M Nagel, Florian Matt, Diana Scholz, Julie Lotharius

Toxicol Appl Pharmacol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels.
Sandra Vergo, Jens Leander Johansen, Marcel Leist, Julie Lotharius

Brain Res· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammation in Parkinson's disease: causative or epiphenomenal?
Andreas Hald, Johan Van Beek, Julie Lotharius

Subcell Biochem· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway.
Julie Lotharius, Jeppe Falsig, Johan van Beek, Sarah Payne, Ralf Dringen

J Neurosci· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
Andreas Hald, Julie Lotharius

Exp Neurol· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Specific modulation of astrocyte inflammation by inhibition of mixed lineage kinases with CEP-1347.
Jeppe Falsig, Peter Pörzgen, Julie Lotharius, Marcel Leist

J Immunol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted expression of BCL-2 attenuates MPP+ but not 6-OHDA induced cell death in dopaminergic neurons.
Karen L O'Malley, Jian Liu, Julie Lotharius, William Holtz

Neurobiol Dis· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Free radicals and ailing proteins--the culprits behind Parkinson disease?].
Ruben Smith, Julie Lotharius, Patrik Brundin

Lakartidningen· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein.
Julie Lotharius, Patrik Brundin

Nat Rev Neurosci· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line.
Julie Lotharius, Sebastian Barg, Pia Wiekop, Cecilia Lundberg, Heather K Raymon

J Biol Chem· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease.
Julie Lotharius, Patrik Brundin

Hum Mol Genet· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis